RXRXRECURSION PHARMACEUTICALS, ...

Nasdaq recursion.com


$ 9.38 $ 0.04 (0.43 %)    

Tuesday, 25-Jun-2024 15:59:55 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 9.38
$ 9.45
$ 0.00 x 0
$ 9.39 x 131
$ 9.31 - $ 9.84
$ 4.97 - $ 16.75
5,159,430
na
2.21B
$ 2.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-27-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 recursion-pharmaceuticals-stock-is-moving-tuesday-whats-happening

Shares of clinical stage biotech company Recursion Pharmaceuticals Inc (NASDAQ:RXRX) are trading higher Tuesday. The company...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-17-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.

 whats-going-on-with-recursion-pharmaceuticals-stock-monday

Recursion Pharmaceuticals shares traded higher Monday after the company provided updated guidance and partnership updates at it...

 helix-recursion-pharmaceuticals-partner-to-drive-drug-discovery-innovation-through-clinico-genomic-data

Access to Helix's large-scale clinico-genomic data to drive creation and training of AI modelsHelix, a leading population g...

 recursion-eyes-guidance-on-seven-clinical-readouts-within-18-months-and-shares-partnership-updates-at-co-download-day

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to ad...

 jim-cramer-offers-his-take-on-corning-calls-this-healthcare-stock-a-terrific-spec

Jim Cramer says Corning has "not been able to generate the kind of return that I've wanted"; calls Recursion a "...

 recursion-pharmaceuticals-stock-surges-10-as-nvidia-powered-supercomputer-completion-sparks-investor-optimism

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) made waves Monday afternoon not only with the announcement of its groundbreaking...

Core News & Articles

 Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today anno...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-17-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.

 nvidia-backed-recursion-pharmaceuticals-stock-is-up-on-q1-earnings-everything-you-need-to-know

Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzi...